BioCardia Shares Decline Amid Regulatory Timing Uncertainty

BioCardia shares are trading lower after the company provided an update on regulatory activities, indicating potential delays in seeking FDA and Japan PMDA approvals for its CardiAMP Cell Therapy and Helix Transendocardial Delivery Catheter.